Apellis Pharmaceuticals, INC Form 4 insider transactions

Apellis Pharmaceuticals' General Counsel, David O. Watson, sold 5,000 shares of common stock at a price of $34.235 per share on December 11, 2024.

Apellis Pharmaceuticals CEO Cedric Francois reported a change in beneficial ownership of company stock due to a divorce settlement, involving a transfer of shares from one trust to his former spouse.

David O. Watson, General Counsel of Apellis Pharmaceuticals, reports changes in his beneficial ownership of company stock due to a distribution from a trust.

Director A. Sinclair Dunlop exercised stock options and reported changes in beneficial ownership of Apellis Pharmaceuticals stock.

Director Sinclair Dunlop reports selling shares of Apellis Pharmaceuticals through a non-Rule 10b5-1 trading plan.

James George Chopas, VP/Chief Accounting Officer of Apellis Pharmaceuticals, sold 192 shares of common stock on September 16, 2024, to cover tax withholding on restricted stock units.

James George Chopas, VP/Chief Accounting Officer of Apellis Pharmaceuticals, sold 550 shares of common stock on September 3, 2024, to cover tax withholding obligations.

Mark Jeffrey DeLong, Chief Business & Strategy Officer of Apellis Pharmaceuticals, exercised stock options and acquired common stock on August 12, 2024.

Director A. Sinclair Dunlop reports exercising stock options and changes in beneficial ownership of Apellis Pharmaceuticals stock.

Director Sinclair A. Dunlop reports sales of Apellis Pharmaceuticals (APLS) stock held directly and indirectly through Epidarex Capital I LP and MASA.

Pascal Deschatelets, Chief Scientific Officer of Apellis Pharmaceuticals, exercised stock options to acquire 24,500 shares of common stock.

Pascal Deschatelets, Chief Scientific Officer of Apellis Pharmaceuticals, exercised stock options and sold shares under a pre-arranged 10b5-1 trading plan.

Timothy Eugene Sullivan, CFO of Apellis Pharmaceuticals, transferred 14,164 shares of common stock to The Timothy E Sullivan Irrevocable Trust of 2023 on April 18, 2024.

Director A. Sinclair Dunlop exercised stock options and reported changes in beneficial ownership of Apellis Pharmaceuticals, Inc. shares.

Pascal Deschatelets, Chief Scientific Officer of Apellis Pharmaceuticals, exercised stock options and sold shares of common stock under a pre-arranged 10b5-1 trading plan on April 8, 2024.

Timothy Eugene Sullivan, CFO of Apellis Pharmaceuticals, executed a pre-planned transaction involving the exercise of stock options and sale of common stock on April 1, 2024.

Director Sinclair Dunlop of Apellis Pharmaceuticals sold 18,681 shares of common stock at an average price of $57.179 on March 19, 2024.

Mark Jeffrey DeLong, Chief Business & Strategy Officer of Apellis Pharmaceuticals, sold 9,913 shares of common stock on March 18, 2024, at a price of $56.9 per share.

James George Chopas, VP/Chief Accounting Officer of Apellis Pharmaceuticals, sold 184 shares of common stock on March 15, 2024, to cover tax obligations related to released Restricted Stock Units.

Nur Nicholson, Chief Technical Officer of Apellis Pharmaceuticals, sold a total of 11,220 shares of common stock in multiple transactions on March 13, 2024.

Pascal Deschatelets, Chief Scientific Officer of Apellis Pharmaceuticals, exercised stock options and sold shares of common stock under a pre-arranged 10b5-1 trading plan on March 8, 2024.

David O. Watson, General Counsel of Apellis Pharmaceuticals, exercised stock options and reported changes in beneficial ownership.

Apellis Pharmaceuticals CEO Cedric Francois exercised stock options and sold shares of common stock on March 1, 2024, under a pre-arranged 10b5-1 trading plan.

Timothy Sullivan, CFO of Apellis Pharmaceuticals, exercised stock options and sold shares of common stock according to a pre-arranged 10b5-1 trading plan.